— Presentation on Thursday, January 14, 2016, at 11:00 a.m. Pacific
BRISBANE, Calif.--(BUSINESS WIRE)--Jan. 6, 2016--
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing desensitization treatments for food allergies, today
announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will present at the
34th Annual J.P. Morgan Healthcare Conference in San Francisco on
Thursday, January 14, 2016, at 11:00 a.m. Pacific Time.
A live audio webcast of the presentation will be accessible from the
Investor Relations section of the Aimmune website at www.aimmune.com.
A replay of the webcast will be available at www.aimmune.com
for 14 days following the event.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical
company developing treatments for peanut allergy and other food
allergies. The company’s characterized oral desensitization
immunotherapy (CODIT™) system, an approach to oral immunotherapy (OIT),
uses rigorously characterized product candidates with gradual,
controlled up-dosing protocols to obtain clinically meaningful
desensitization to food allergens. Aimmune Therapeutics plans to
initiate enrollment in a Phase 3 study of its lead product, AR101, a
complex mixture of natural peanut proteins and pharmaceutical-grade
ingredients for the treatment of peanut allergy, one of the most common
food allergies, at the beginning of 2016. AR101 has received the FDA’s
Breakthrough Therapy Designation for the desensitization of
peanut-allergic patients 4-17 years of age. For more information, please
View source version on businesswire.com: http://www.businesswire.com/news/home/20160106005728/en/
Source: Aimmune Therapeutics, Inc.
Stern Investor Relations
Beth DelGiacco, 212-362-1200